Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): An open-label, single-arm, phase II study. This is an ASCO Meeting ...

After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer Neoadjuvant approaches ...

Rapid developments in muscle-invasive bladder cancer treatment are leading to new approaches to bladder preservation.

ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy. In this study, R, a bispecific checkpoint ...

In a phase 2 trial of nonurothelial MIBC, half of patients receiving neoadjuvant chemoimmunotherapy showed no residual cancer at the time of surgery. The single-center, phase 2 trial included 17 ...

Growing support for perioperative vs neoadjuvant therapy, but many questions yet to be ans ...